Search
iCo-007
go.drugbank.com/drugs/DB05268Investigational) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
Patent Blue
go.drugbank.com/drugs/DB13967ApprovedInvestigational[A32573] It is a sodium or calcium salt of diethylammonium hydroxide inner salt.
Categories: Compounds used in a research, industrial, or household settingGestrinone
go.drugbank.com/drugs/DB11619ApprovedHowever, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis. … Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America.
Davamotecan pegadexamer
go.drugbank.com/drugs/DB05899InvestigationalEP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].
Categories: Compounds used in a research, industrial, or household settingAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigational[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies … Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigationalDabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalFabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). … unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients.
Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological ChaperonesBeclamide
go.drugbank.com/drugs/DB09011ExperimentalBeclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.